Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis

Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks the joint lining, while osteoarthritis (OA) is a degenerative disease of the whole joint driven by mechanical load, age and metabolic stress. According to the CDC, 53.2 million US adults (21.2%) had diagnosed arthritis in 2019 to 2021, and the Global Burden of Disease Study estimated that 595 million people worldwide had osteoarthritis in 2020.

The two diseases need different treatment. RA is controlled with disease-modifying antirheumatic drugs (DMARDs) prescribed by a rheumatologist, while OA care starts with exercise, weight management and physical therapy. Regenerative options such as platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), prolotherapy and peptides sit on top of that care, and the evidence for each is graded below.

Table of Contents

• RA vs. OA: Two Different Diseases
• Rheumatoid Arthritis: Pathophysiology
• Osteoarthritis: Pathophysiology
• Diagnosis and Classification
• Conventional Treatment for RA
• Conventional Treatment for OA
• Platelet-Rich Plasma (PRP)
• Stem Cell Therapy
• Peptides and Small Molecules
• Other Regenerative Approaches
• Evidence Summary Table
• What to Expect from Treatment
• Frequently Asked Questions

RA vs. OA: Two Different Diseases

Arthritis is not a single disease. It is a category covering over 100 joint conditions, but rheumatoid arthritis and osteoarthritis account for the vast majority of cases and carry the greatest burden of disability. Despite sharing the word “arthritis,” their causes, mechanisms, and optimal treatments are fundamentally different.

Confusing the two leads to mismanagement. A patient treated for OA who actually has RA may experience ongoing joint destruction while waiting for symptom relief. A patient given immunosuppressive DMARD therapy for mechanical wear risks unnecessary side effects. Accurate diagnosis is the foundation of effective care.

The table below sets out the features clinicians use to tell rheumatoid arthritis from osteoarthritis. A longer side-by-side comparison, including which tests settle the question, is in osteoarthritis vs. rheumatoid arthritis.

Feature	Rheumatoid Arthritis (RA)	Osteoarthritis (OA)
Primary cause	Autoimmune dysregulation	Mechanical wear, metabolic stress
Age of onset	Typically 30-60 years	Typically 50+ years
Joints affected	Small joints (MCP, PIP, wrists), bilateral and symmetric	Weight-bearing joints (knee, hip), also hands (DIP)
Morning stiffness	Over 1 hour (characteristic)	Under 30 minutes
Systemic symptoms	Fatigue, fever, weight loss	Absent or mild
Inflammatory markers	Elevated CRP, ESR; positive RF/anti-CCP	Normal or mildly elevated
X-ray findings	Erosions, periarticular osteopenia	Joint space narrowing, osteophytes, subchondral sclerosis
Synovitis	Prominent, aggressive pannus formation	Low-grade, secondary

What are the main types of arthritis?

Arthritis means inflammation or degeneration of a joint, and clinicians group its more than 100 forms into degenerative, autoimmune, crystal and infectious types. Osteoarthritis is the most common type overall, and rheumatoid arthritis is the most common autoimmune type. The type decides whether treatment targets the immune system, the joint surface, uric acid or an infection.

The sections that follow focus on RA and OA because they cause most arthritis disability and because most regenerative clinics treat them. Skin plaques with joint pain point toward psoriatic arthritis, covered in signs of psoriatic arthritis. Joint swelling after a gut or urinary infection is described in the post on reactive arthritis.

What are the early signs of rheumatoid arthritis and osteoarthritis?

The earliest sign of rheumatoid arthritis is usually swelling, warmth and tenderness in several small joints of both hands or feet, with morning stiffness lasting more than an hour. The earliest sign of osteoarthritis is pain in one or a few joints that worsens with use and eases with rest, with stiffness after sitting that settles within about 30 minutes.

Rheumatoid arthritis symptoms

• Swollen, tender knuckles (MCP joints), middle finger joints (PIP joints), wrists and balls of the feet, usually on both sides of the body.
• Morning stiffness that lasts longer than an hour and improves with movement.
• Whole-body symptoms such as fatigue, low-grade fever, poor appetite and weight loss.
• Firm rheumatoid nodules under the skin near the elbows or fingers in some people.
• Effects outside the joints, including dry eyes and mouth (secondary Sjogren syndrome), lung involvement and a higher risk of cardiovascular disease.

A fuller list, including how symptoms change over the first year, is in the post on early rheumatoid arthritis symptoms.

Osteoarthritis symptoms

• Deep, aching pain in the knee, hip, base of the thumb or end finger joints that builds with walking, climbing stairs or gripping.
• Short stiffness after rest, sometimes called gelling, that eases within minutes of moving.
• Grating or crackling (crepitus) and reduced range of motion.
• Bony enlargement at the finger joints, called Heberden nodes at the end joints and Bouchard nodes at the middle joints.
• Knee buckling, locking or a sense of instability as the joint changes shape.

Hip pain felt in the groin or front of the thigh is a common OA pattern, described on the hip osteoarthritis page. Hand involvement is covered in arthritis in the hands.

When does joint pain need prompt care?

A single hot, red, swollen joint with fever needs same-day evaluation, because septic arthritis can damage cartilage quickly and is treated with drainage and antibiotics. New swelling in several joints that lasts six weeks or longer deserves a rheumatology referral, since the 2010 ACR/EULAR criteria use that duration and early DMARD therapy protects joints.

Rheumatoid Arthritis: Pathophysiology

RA begins with a loss of immune tolerance to self-antigens, particularly citrullinated proteins. In genetically susceptible individuals (especially those carrying HLA-DRB1 “shared epitope” alleles), environmental triggers, most notably cigarette smoking, appear to initiate protein citrullination in the lungs or other mucosal surfaces. This generates anti-citrullinated protein antibodies (ACPA), detectable in serum years before clinical joint symptoms appear.

Once synovial inflammation is established, a self-amplifying cascade drives joint destruction. Activated CD4+ T cells stimulate B cells to produce autoantibodies (RF, ACPA) and drive macrophage activation. Macrophages release pro-inflammatory cytokines, primarily TNF-alpha, IL-1, and IL-6. These cytokines stimulate synovial fibroblasts to proliferate, forming the invasive pannus tissue that erodes cartilage and bone. Osteoclast activation, driven by receptor activator of NF-kB ligand (RANKL), accelerates periarticular bone loss.

The synovium transforms from a thin membrane into an aggressive, tumor-like tissue. Synovial fibroblasts in RA acquire an invasive phenotype independent of lymphocyte signaling, which partly explains why remission is difficult to sustain and why certain patients do not respond fully to biologic therapies targeting T or B cells.

Genetic and Environmental Risk

Heritability of RA is estimated at 40-60%, with HLA-DRB1 alleles accounting for roughly 30% of genetic risk. Non-HLA loci, including PTPN22, CTLA4, and STAT4, contribute additional susceptibility. A 2014 genome-wide association meta-analysis by Okada et al., published in Nature, identified 101 RA risk loci, pointing to multiple immune regulatory pathways involved in disease onset.

Cigarette smoking is the strongest modifiable environmental risk factor, roughly doubling RA risk in genetically susceptible individuals. Periodontal disease (via Porphyromonas gingivalis citrullination activity), gut dysbiosis, and hormonal factors also appear to contribute. Women are affected two to three times more often than men, suggesting a role for sex hormones in immune regulation.

Osteoarthritis: Pathophysiology

OA was historically described as simple “wear and tear,” but this framing is now considered inadequate. OA involves active biological remodeling of the entire joint unit, including articular cartilage, subchondral bone, synovium, ligaments, and periarticular muscles. It is better understood as a failure of joint homeostasis driven by a combination of mechanical overload and metabolic dysfunction.

At the cellular level, chondrocytes shift from a quiescent maintenance state toward a hypertrophic, catabolic phenotype. They upregulate matrix metalloproteinases (MMPs) and ADAMTS enzymes that degrade aggrecan and type II collagen, the primary structural components of cartilage. This degradation outpaces repair capacity, leading to progressive cartilage thinning. Subchondral bone undergoes concurrent remodeling, with increased vascularity and altered stiffness that further disrupts load distribution across the joint surface.

Low-grade synovial inflammation, while less dramatic than in RA, is present in most OA joints and contributes meaningfully to pain. Synovial macrophages release IL-1beta and TNF-alpha in OA joints, creating a local inflammatory microenvironment. A 2021 review in Nature Reviews Rheumatology highlighted that OA synovitis correlates with pain severity and structural progression, challenging the view that OA is a purely mechanical condition.

Risk Factors for OA

Age is the strongest risk factor. Cartilage repair capacity decreases with age due to reduced chondrocyte numbers and mitochondrial dysfunction. Obesity amplifies risk through both mechanical loading and systemic metabolic effects: adipokines from visceral fat directly promote chondrocyte catabolism. A body mass index above 30 roughly quadruples knee OA risk compared to normal weight.

Prior joint injury is a significant independent risk factor. Post-traumatic OA develops in 50-80% of individuals following ligament or meniscal injuries, according to data published in Osteoarthritis and Cartilage (2019). Female sex, occupational joint loading, and certain genetic polymorphisms in collagen and cartilage matrix genes also increase susceptibility.

Diagnosis and Classification

Diagnosing RA

The 2010 ACR/EULAR classification criteria for RA replaced the older 1987 criteria to allow earlier diagnosis before erosive disease develops. The scoring system considers the number and type of joints involved, serologic findings (RF, ACPA), acute phase reactants (CRP, ESR), and symptom duration. A score of 6 or more out of 10 classifies a patient as having definite RA.

Anti-CCP (cyclic citrullinated peptide) antibodies have approximately 95% specificity for RA and can precede clinical onset by years. Their presence alongside joint symptoms strongly supports early treatment initiation. Seronegative RA (negative RF and anti-CCP) exists in roughly 20-30% of cases and can be diagnostically challenging.

Seronegative patients are often diagnosed later because normal antibody tests can look reassuring, and the seronegative rheumatoid arthritis page covers how ultrasound and MRI help. Typical early findings are described on the rheumatoid arthritis condition page.

Diagnosing OA

OA diagnosis is primarily clinical and radiographic. The ACR criteria for knee OA require knee pain plus at least three of the following: age over 50, morning stiffness under 30 minutes, crepitus on motion, bony tenderness, bony enlargement, or absence of warmth. Radiographic OA is classified by the Kellgren-Lawrence (KL) grading system, from grade 0 (normal) to grade 4 (severe joint space loss with large osteophytes).

MRI is increasingly used to detect early cartilage changes before radiographic findings appear, and is particularly relevant for clinical trials and surgical decision-making. Synovial fluid analysis in OA typically shows a non-inflammatory profile (white cell count under 2,000 cells/mm3), which helps differentiate it from inflammatory arthropathies.

Who treats arthritis?

Rheumatologists diagnose and manage rheumatoid arthritis, psoriatic arthritis and other inflammatory types, and they prescribe and monitor DMARDs, biologics and JAK inhibitors. Osteoarthritis is usually managed by primary care physicians, sports medicine physicians, physiatrists and orthopedic surgeons, with physical therapists delivering the exercise programs that guidelines put first.

• Rheumatologist: confirms RA or another inflammatory arthritis, orders RF, anti-CCP, CRP and ESR, and runs treat-to-target therapy.
• Primary care physician (internal or family medicine): usually the first stop for joint pain, orders initial X-rays and labs, and manages most OA.
• Physiatrist (physical medicine and rehabilitation) or sports medicine physician: treats OA without surgery and often performs ultrasound-guided injections, including corticosteroid, hyaluronic acid and PRP.
• Orthopedic surgeon: evaluates advanced OA for osteotomy or total joint replacement.
• Physical and occupational therapists: build strength and range-of-motion programs, fit braces and splints, and teach joint protection.
• Interventional pain physician: offers nerve-targeted procedures such as genicular nerve radiofrequency ablation for knee OA pain.
• Regenerative and integrative medicine clinics: physicians (MD or DO), nurse practitioners and physician assistants who offer PRP, prolotherapy, cell-based injections, peptides or ozone, usually as cash-pay services.

The strongest plans keep these roles connected. A regenerative injection for knee OA works best alongside physical therapy, and RA patients exploring cell therapy should keep their rheumatologist involved. The broader picture of joint pain causes helps when the diagnosis is still unclear.

Conventional Treatment for RA

The treatment goal in RA is remission or low disease activity, guided by a treat-to-target (T2T) strategy formalized in ACR and EULAR guidelines. Disease activity is measured regularly using validated scores such as the DAS28 (Disease Activity Score), and therapy is escalated until the target is reached.

The American College of Rheumatology (ACR) published its current RA guideline in 2021 (Fraenkel et al.), and the European Alliance of Associations for Rheumatology (EULAR) updates its recommendations every few years. Both put methotrexate first for most patients. Each drug class below, along with investigational options, is compared in the post on rheumatoid arthritis treatment options.

Conventional DMARDs

Methotrexate (MTX) remains the anchor drug for RA. It is typically the first DMARD initiated after diagnosis, at doses of 7.5-25 mg per week. MTX works through multiple mechanisms including folate pathway inhibition and adenosine pathway modulation, resulting in reduced inflammation and slowed joint destruction. A 2019 Cochrane review of 17 trials confirmed that MTX significantly reduces disease activity and structural progression versus placebo.

Other conventional DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine, often used in combination. Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) can be as effective as biologic therapy in some patients and is substantially less expensive, according to a landmark 2013 trial published in The New England Journal of Medicine.

Biologic DMARDs

Biologic agents target specific cytokines or immune cells in the RA cascade. TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab, golimumab) were the first approved and remain widely used. IL-6 receptor inhibitors (tocilizumab, sarilumab) are effective, particularly in patients who fail TNF inhibition. Abatacept (CTLA4-Ig) targets T cell co-stimulation, and rituximab depletes B cells.

Biologic therapy combined with MTX produces ACR50 responses (50% improvement in disease activity measures) in 40-60% of patients, with ACR70 responses in 25-40%, based on pooled data from pivotal trials. These are meaningful improvements, but a substantial proportion of patients do not achieve sustained remission.

JAK Inhibitors

Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and upadacitinib, block intracellular signaling downstream of multiple cytokine receptors. They are oral agents that offer an alternative to injectable biologics. A 2018 Phase 3 trial of upadacitinib published in The Lancet (SELECT-BEYOND, n=499) showed ACR20 rates of 65% and remission rates of 25% in patients who had failed biologic therapy.

The FDA and EMA have added safety warnings regarding cardiovascular events, venous thromboembolism, and malignancy risk with JAK inhibitors, based on the ORAL Surveillance trial (2022, NEJM), which showed higher rates of major adverse cardiovascular events and cancers with tofacitinib versus TNF inhibitors in a high-cardiovascular-risk population. These drugs are generally reserved for patients who have failed or cannot tolerate conventional DMARDs and at least one biologic.

Conventional Treatment for OA

OA treatment guidelines from ACR (2019 update) and OARSI (2019) strongly recommend exercise therapy, weight management, and physical therapy as first-line interventions. These have the best risk-benefit ratios and should be initiated before or alongside any pharmacologic therapy. A 2017 meta-analysis in JAMA Internal Medicine found that land-based exercise reduces knee OA pain by an average of 12 points on a 100-point scale (NRS).

OARSI, the Osteoarthritis Research Society International, and the UK National Institute for Health and Care Excellence (NICE) reach the same order of care. The post on osteoarthritis treatment steps walks through each one, and the osteoarthritis condition overview explains staging by joint.

Pharmacologic Options

Topical NSAIDs (diclofenac gel) are the preferred first pharmacologic step for knee and hand OA, offering similar efficacy to oral NSAIDs with much lower systemic exposure. Oral NSAIDs are conditionally recommended but carry significant gastrointestinal, cardiovascular, and renal risks with long-term use. Duloxetine is recommended for patients with widespread pain or a significant central sensitization component.

Intra-articular corticosteroid injections provide short-term pain relief (typically 4-6 weeks) but have not been shown to slow structural progression. A 2017 JAMA study (n=140) found that repeated corticosteroid injections over 2 years actually resulted in greater cartilage volume loss compared to saline injections, raising concerns about long-term use. Intra-articular hyaluronic acid (viscosupplementation) has inconsistent evidence; ACR 2019 guidelines conditionally recommend against it for knee OA due to small effect sizes.

Surgical Options

Total joint replacement (TJR) is effective for end-stage OA with severe pain and functional limitation unresponsive to conservative management. Knee and hip replacements have over 90% implant survival at 10 years. Arthroscopic surgery (debridement, lavage) is not recommended for knee OA per ACR and NICE guidelines, based on multiple sham-controlled trials showing no benefit over conservative care.

What can you do at home to manage arthritis?

Exercise and weight management are the self-care steps with the strongest evidence for osteoarthritis. The 2019 American College of Rheumatology guideline (Kolasinski et al.) strongly recommends exercise, weight loss for people with overweight or obesity, tai chi, self-management programs and a cane for knee and hip OA. People with RA benefit from the same activity habits, and quitting smoking matters most because smoking is linked with more severe disease.

1. Move most days. Combine low-impact aerobic activity such as walking, cycling or water exercise with two or more days of strength training, following the federal Physical Activity Guidelines for Americans.
2. Strengthen the muscles around the joint. Quadriceps and hip strengthening reduce knee load; a physical therapist can set the starting level. See osteoarthritis exercises for examples.
3. Lose weight if it is above a healthy range. Less body weight lowers the mechanical load on knees and hips and reduces the adipokines that drive cartilage breakdown.
4. Join a structured program. The CDC recognizes community self-management and walking programs, such as Walk With Ease, that teach pacing and pain coping skills.
5. Protect RA joints and overall health. Stop smoking, keep up dental care because periodontal disease is linked to RA, get vaccines updated before starting immunosuppressive drugs, and protect sleep, which affects pain and fatigue.
6. Use aids that guidelines support. A cane for hip or knee OA, a knee brace for tibiofemoral OA and a thumb splint for base-of-thumb OA can lower pain during daily tasks.

Diet changes help as an adjunct, and the evidence is summarized in the dietary section under Other Regenerative Approaches below and in the post on the rheumatoid arthritis diet.

Platelet-Rich Plasma (PRP)

PRP is prepared by centrifuging a patient’s own blood to concentrate platelets, which contain growth factors including PDGF, TGF-beta, IGF-1, VEGF, and FGF. When injected into a joint, these growth factors may modulate the local inflammatory environment, stimulate chondrocyte activity, and inhibit catabolic enzymes.

PRP is also called platelet-rich plasma therapy, platelet injection or an orthobiologic injection, and it belongs to the same family as prolotherapy and cell-based injections. Physiatrists, sports medicine physicians and orthopedic surgeons usually give it under ultrasound guidance in a single office visit. The platelet-rich plasma treatment guide covers preparation and aftercare, and the post on PRP injections for the knee goes deeper on that joint.

Evidence in Osteoarthritis

The evidence base for intra-articular PRP in knee OA has grown substantially over the past decade. Most meta-analyses of randomized trials find that PRP reduces knee OA pain more than hyaluronic acid or corticosteroid injections at 6 to 12 months. Trial quality, PRP preparation and patient selection vary widely, which limits how far those pooled results can be trusted.

The 2021 RESTORE trial by Bennell et al. in JAMA (n=288), a double-blind RCT comparing leukocyte-poor PRP with saline placebo in knee OA, found no significant difference in knee pain or in medial tibial cartilage volume at 12 months. This trial tempered enthusiasm somewhat and underscored the importance of patient selection, PRP preparation method, and injection technique as variables affecting outcome.

Key variables affecting outcomes include leukocyte content (leukocyte-poor PRP appears better tolerated in joints), platelet concentration, number of injections, and baseline disease severity. Patients with early to moderate OA (KL grade 1-3) appear to derive more benefit than those with severe structural disease (KL grade 4).

Evidence in Rheumatoid Arthritis

Research on PRP in RA is limited and the theoretical rationale is less clear. RA involves an active autoimmune process, and introducing concentrated growth factors and cytokines into an already inflamed joint could theoretically amplify inflammation. Small pilot studies have suggested possible benefit in finger joints, but no adequately powered RCTs exist. PRP for RA joints should be considered investigational at this stage.

Stem Cell Therapy

Mesenchymal stem cells (MSCs) are multipotent stromal cells found in bone marrow, adipose tissue, umbilical cord tissue (Wharton’s jelly), and synovial membrane. They have two properties of relevance to arthritis treatment: the ability to differentiate toward chondrogenic lineages, and potent immunomodulatory activity through paracrine signaling (secretion of anti-inflammatory cytokines and extracellular vesicles).

MSC Therapy in OA

A 2020 systematic review in Stem Cells Translational Medicine analyzed 23 clinical studies of MSC injection for knee OA and found consistent signals of pain reduction and functional improvement at 6-12 months. MRI-based studies in several trials suggested partial cartilage regeneration, though image interpretation requires caution given variability in scoring methods.

A Phase 1 dose-escalation trial by Pers et al., published in Stem Cells Translational Medicine (2016, n=18), found that adipose-derived MSC injection in severe knee OA was well tolerated and was followed by improvements in pain and function, most clearly at the low dose. The trial had no control group, and sample sizes in most MSC trials remain small.

The source of MSCs (autologous vs. allogeneic), cell dose, preparation method, and delivery technique (injection vs. scaffold-based implantation) all influence outcomes significantly. Umbilical cord-derived MSCs (UC-MSCs) are increasingly used due to higher proliferative capacity and lower immunogenicity, and can be banked and deployed off-the-shelf, unlike autologous preparations that require individual processing.

Clinics describe these products as stem cell injections, cell-based therapy, bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF) or umbilical cord tissue, and those labels are not interchangeable. BMAC and SVF contain a small fraction of true MSCs mixed with other cells, while culture-expanded MSCs for arthritis are available in the US only through clinical trials. The stem cell therapy guide explains each source, and stem cell therapy for arthritis reviews joint-specific results.

MSC Therapy in RA

The immunomodulatory properties of MSCs make them particularly relevant for RA. MSCs suppress T cell proliferation, shift the balance from Th17 toward Treg cells, and inhibit B cell differentiation, actions that could interrupt the RA autoimmune cascade. A prospective Phase 1/2 study published in Drug Design, Development and Therapy (2019) gave intravenous UC-MSC infusions with DMARDs to patients with RA and reported lower ESR, CRP, DAS28 and HAQ scores at 1 and 3 years than at baseline, with no laboratory safety signals. A Phase 1a trial of umbilical cord blood MSCs in Stem Cells Translational Medicine (2018) reported similar early safety findings, and randomized, placebo-controlled trials are still needed.

Intravenous MSC delivery for RA differs mechanistically from intra-articular injection for OA. Systemic delivery targets the immune system broadly rather than providing local joint support. Most MSCs do not engraft long-term after IV infusion; their benefit appears to be mediated primarily through transient paracrine effects on immune cells in lymphoid organs and inflamed tissues.

Hematopoietic Stem Cell Transplantation (HSCT) for RA

Autologous HSCT, which involves immune ablation followed by reconstitution with the patient’s own hematopoietic stem cells, has been studied in severe, refractory RA since the late 1990s. The goal is to “reset” the autoreactive immune system. A 2013 long-term follow-up study from the EULAR registry reported drug-free remission in 10-20% of treated patients at 5 years. HSCT carries significant treatment-related morbidity and is reserved for patients with very aggressive, refractory disease who have failed multiple biologics.

Peptides and Small Molecules

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein. In animal studies, it has shown consistent anti-inflammatory effects, upregulation of growth hormone receptor expression, and acceleration of tendon and ligament healing. A 2018 rodent study in Journal of Physiology and Pharmacology demonstrated reduced joint inflammation and improved mobility in collagen-induced arthritis models.

Human clinical trial data for BPC-157 is essentially absent for arthritis. The peptide is not approved by any major regulatory agency and is currently available only through compounding pharmacies or research suppliers. Its use in clinical practice is off-label and experimental. Claims about BPC-157 in humans should be treated with caution until controlled trials are completed.

Peptides are prescribed through cash-pay peptide therapy programs, usually as daily subcutaneous injections compounded by a pharmacy. Product purity and dose vary between suppliers, which is a separate risk from the lack of trial data. More detail is in the BPC-157 treatment overview.

TB-500 (Thymosin Beta-4)

Thymosin beta-4 is an endogenous peptide involved in actin polymerization, cell migration, and tissue repair. It has shown anti-inflammatory and angiogenic properties in preclinical studies. Synthetic versions (TB-500) are used experimentally for soft tissue injuries. Relevant to OA, a 2020 study in Osteoarthritis and Cartilage found that thymosin beta-4 reduced synovial inflammation and cartilage degradation in a mouse OA model by inhibiting NF-kB signaling. Human evidence is lacking.

Low-Dose Naltrexone (LDN)

LDN (typically 1.5-4.5 mg/day, compared to the 50 mg anti-addiction dose) acts as a transient opioid receptor antagonist, triggering a rebound upregulation of endogenous opioid tone and modulation of microglial/macrophage activity via Toll-like receptor 4 (TLR4) antagonism. This makes it relevant for both inflammatory and pain conditions.

A 2020 pilot RCT published in Pain Medicine (n=40) evaluated LDN for fibromyalgia and chronic widespread pain and found significant pain reduction. RA-specific LDN trials are limited to case reports and small open-label series. A 2018 review in Pharmacological Research summarized preclinical data showing LDN reduces TNF-alpha, IL-6, and NF-kB activity in inflammatory models, suggesting biological plausibility for RA application.

Other Regenerative Approaches

Prolotherapy

Prolotherapy involves injection of an irritant solution (typically dextrose) into ligamentous and tendinous attachments around a joint to stimulate a local healing response. A 2013 RCT by Rabago et al. in Annals of Family Medicine (n=90) found that dextrose prolotherapy improved knee OA WOMAC scores significantly more than blinded saline injection or at-home exercise at 52 weeks. Evidence is Moderate for OA but limited for RA.

The prolotherapy treatment guide explains how dextrose injections differ from PRP, and prolotherapy vs. PRP compares cost drivers and evidence for the knee.

Hyperbaric Oxygen Therapy (HBOT)

HBOT involves breathing 100% oxygen in a pressurized chamber (typically 1.5-2.4 atmospheres). Proposed mechanisms in arthritis include reduced hypoxia in inflamed synovium, inhibition of NF-kB activation, and enhanced neutrophil killing of pathogens. A 2022 systematic review in Frontiers in Medicine found seven small studies of HBOT in RA, with mixed results and significant methodological limitations. Evidence remains Preliminary.

HBOT is FDA cleared for indications such as decompression sickness and diabetic foot wounds, not for arthritis, so its use for joint disease is off label. The hyperbaric oxygen therapy guide lists the approved indications.

Dietary and Nutritional Interventions

Anti-inflammatory dietary patterns have documented effects on RA and OA outcomes. A Mediterranean diet intervention in a 2018 RCT published in Annals of the Rheumatic Diseases (n=66) produced meaningful reductions in DAS28 scores and self-reported pain in RA patients over 12 weeks compared to a standard Western diet. Omega-3 supplementation (2-4 g EPA+DHA daily) has been shown in multiple small RCTs to reduce NSAID use in RA, with a 2012 meta-analysis in Annals of the Rheumatic Diseases confirming morning stiffness and joint tenderness reductions.

For OA, a 2021 Cochrane review on dietary supplements found low to moderate evidence for glucosamine sulfate and chondroitin sulfate in reducing pain, but significant heterogeneity between trials and industry funding concerns complicate the picture. Curcumin at 1,500 mg/day showed comparable pain reduction to ibuprofen 1,200 mg/day in a 2014 Thai RCT (n=367), with a better gastrointestinal side effect profile.

Evidence Summary Table

Treatment	Condition	Evidence Level	Key Findings
Conventional DMARDs (MTX)	RA	Strong	Standard of care; slows erosive progression in majority of patients
Biologic DMARDs (TNFi, IL-6i)	RA	Strong	ACR50 in 40-60%; effective in DMARD-inadequate responders
JAK inhibitors	RA	Strong (with caveats)	Effective; cardiovascular/malignancy safety warnings in high-risk patients
Exercise therapy	OA	Strong	Best risk-benefit ratio; first-line recommendation per ACR/OARSI
Topical NSAIDs	OA	Strong	Effective for knee/hand OA with low systemic risk
PRP injection	OA (knee)	Moderate	Outperforms HA in most meta-analyses; 2021 JAMA RCT showed no benefit vs. saline
MSC therapy (intra-articular)	OA	Emerging	Consistent pain/function signals; cartilage repair suggested on MRI in small trials
MSC therapy (IV)	RA	Emerging	Phase 1/2 data promising; larger RCTs needed
Prolotherapy (dextrose)	OA	Moderate	Multiple RCTs show pain/function benefit over saline
HSCT	RA (refractory)	Moderate	Drug-free remission in minority; significant procedural risk
LDN	RA/OA	Preliminary	Biological plausibility; no dedicated arthritis RCTs completed
BPC-157	OA/RA	Preliminary	Animal data only for arthritis; no human trials
HBOT	RA	Preliminary	Small mixed studies; no definitive benefit established

Are PRP and stem cell injections for arthritis FDA approved, and does insurance cover them?

No stem cell or other regenerative medicine product is FDA approved to treat osteoarthritis or rheumatoid arthritis. The FDA states that regenerative medicine therapies have not been approved for the treatment of any orthopedic condition, such as osteoarthritis, and it warns about clinics marketing unapproved stem cell, umbilical cord blood, Wharton’s jelly and exosome products.

How the FDA treats PRP and cell-based injections

The centrifuge systems used to prepare PRP are FDA-cleared devices, but injecting PRP into an arthritic joint is an off-label use that the FDA has not reviewed for that purpose. Same-day procedures that use a patient’s own minimally manipulated tissue, such as bone marrow aspirate concentrate (BMAC), fall under lighter rules for human cells and tissues (21 CFR Part 1271). Culture-expanded MSCs and donor umbilical cord or Wharton’s jelly products are regulated as biologic drugs and need FDA approval, which none has for arthritis, so outside a registered trial they are unapproved.

Insurance and cost

Medicare and most private insurers treat PRP, stem cell and exosome injections for arthritis as investigational, so patients usually pay cash. Prices vary widely by product, joint, imaging guidance and region, and a single quoted figure rarely includes follow-up visits. Conventional care, including DMARDs, biologics with prior authorization, physical therapy, corticosteroid injections and joint replacement, is generally covered.

Before paying, ask for a written quote that names the product, the number of injections, whether ultrasound or fluoroscopic guidance is included, and the follow-up schedule. Trials listed on ClinicalTrials.gov offer another route, often at no cost to participants, with outcome tracking built in. Background on cell-free products is in the exosome therapy overview.

What to Expect from Treatment

Setting Realistic Goals for RA

Modern RA treatment, using a treat-to-target approach with early aggressive DMARD therapy, has dramatically changed outcomes over the past two decades. Achieving remission is a realistic goal for many patients, particularly those diagnosed early (within 3-6 months of symptom onset) and started on effective therapy promptly. The window of opportunity concept suggests that early intervention, before the establishment of persistent synovitis and fibroblast-driven pannus, produces better long-term structural outcomes.

For patients who reach remission and sustain it for 6-12 months, gradual dose reduction or tapering of biologic therapy is possible and can succeed in 30-40% of cases, according to a 2016 Cochrane review. Full drug discontinuation remains achievable in a minority, underlining the importance of ongoing monitoring even in apparent remission.

Setting Realistic Goals for OA

OA cannot currently be reversed with any available therapy, conventional or regenerative. The realistic treatment goals are pain reduction, functional improvement, slowing of structural progression, and delaying or avoiding joint replacement surgery. Patients with early-stage OA (KL 1-2) and relatively preserved cartilage are the best candidates for regenerative interventions like PRP or MSC therapy.

Patients with KL grade 3-4 disease and severe symptoms have lower response rates to regenerative therapies and should have joint replacement discussed as part of their care plan. Regenerative interventions in advanced OA may still provide temporary symptom relief but are unlikely to produce structural restoration at this stage of disease.

Treatment Sequence and Integration

For most patients, regenerative therapies should be considered adjuncts to, not replacements for, evidence-based conventional care. In OA, this means ensuring an adequate exercise and weight management program is in place before or alongside any injection therapy. In RA, MSC trials are generally conducted in patients who have failed conventional treatment, which remains the appropriate paradigm for most clinical settings outside of specialized research centers.

Patients considering regenerative treatments should be evaluated by a specialist with experience in both conventional rheumatologic care and regenerative medicine to ensure appropriate patient selection and to monitor for adverse effects. Unregulated clinic offerings of stem cell or PRP treatments without diagnostic workup or outcome tracking are a significant quality concern.

How to find an arthritis treatment clinic

Regenerated.com lists US clinics that offer arthritis care and regenerative treatments, and the national directory of arthritis treatment clinics is the place to start. Each listing shows the treatments a clinic offers, so you can narrow by state and city and then check providers against the questions below. For background before you call, the arthritis treatment guide compares conventional and regenerative options in one place.

Listing order on Regenerated.com is not paid ranking. Featured slots are labeled and capped, Verified means the clinic completed credential checks, not that it spent money with us, and the directory is free for patients. Inclusion in the directory is not an endorsement, and the guide to how Featured, Verified and organic listings differ explains each label.

If you already know the treatment you want, you can browse providers offering PRP injections or clinics that offer stem cell therapy directly. State pages narrow it further, for example arthritis clinics in Florida and arthritis treatment providers in Texas.

Questions to ask before booking a regenerative arthritis treatment

1. Who confirmed my diagnosis, and did that include X-rays or MRI and, for suspected RA, RF and anti-CCP blood tests?
2. Who performs the injection, what are their credentials, and is it done under ultrasound or fluoroscopic guidance?
3. What exactly is injected: leukocyte-poor or leukocyte-rich PRP, my own cells or donor tissue, and what is its FDA status?
4. How will you measure whether it worked, for example with WOMAC or KOOS scores for OA or DAS28 for RA, and when are follow-up visits?
5. What is the full cost in writing, and what happens if I do not respond?
6. Will you share results with my rheumatologist or primary care physician?

Frequently Asked Questions

Can PRP reverse osteoarthritis?

No. PRP can ease pain and improve function for several months to over a year in some people with knee osteoarthritis, but no trial has shown that it rebuilds lost cartilage or halts structural progression. The 2021 RESTORE trial in JAMA found no difference from saline in knee pain or cartilage volume at 12 months. PRP is best viewed as a symptom-modifying injection whose possible disease-modifying effects still need larger, longer trials.

Is stem cell therapy for arthritis safe?

Published trials of intra-articular and intravenous mesenchymal stem cell (MSC) therapy report low rates of serious adverse events, and the most common side effect is a temporary flare of joint pain and swelling after injection. Long-term safety beyond 2-3 years is less well characterized. The FDA has not approved any stem cell product for osteoarthritis or rheumatoid arthritis, so a registered clinical trial or an academic center that tracks outcomes carries the least uncertainty.

Do I need to stop my DMARD before trying a regenerative therapy?

Usually not, and stopping a DMARD on your own is risky. For intra-articular PRP in osteoarthritis, DMARDs are generally not an issue because the indication differs from RA. Most MSC trials in rheumatoid arthritis kept patients on stable doses of conventional DMARDs and added cell therapy on top. Unsupervised withdrawal can trigger flares that cause permanent joint damage, so any medication change belongs with your rheumatologist.

How many PRP injections are needed for knee OA?

Most clinical protocols for knee OA use 1-3 PRP injections given 1-4 weeks apart, with a possible repeat series at 6-12 months if the first round helped. No single protocol has been validated across trials, and the best number of injections, interval and platelet dose are still being studied. Ask any clinic which PRP preparation it uses, whether it is leukocyte-poor, and how it will measure your response.

Can diet alone control RA?

No. Diet is a useful adjunct but cannot replace DMARD therapy in established rheumatoid arthritis. A Mediterranean-style diet and omega-3 fats have reduced pain, stiffness and inflammatory markers in small trials, yet no diet has been shown to prevent joint erosions without medication. The practical approach is to improve diet alongside methotrexate or other DMARDs and to review supplements with your rheumatologist, because some interact with drugs.

What distinguishes a legitimate regenerative clinic from a problematic one?

A legitimate regenerative program confirms your diagnosis with imaging and lab work, explains in writing that the treatment is experimental or off label, uses defined outcome measures, schedules follow-up visits, and refers you back to rheumatologic care if your condition worsens. Warning signs include promises of permanent results, no diagnostic workup, no follow-up plan, no disclosure of regulatory status, and prices far above standard care without a clear explanation.

---

Related Reading

• BPC-157 Benefits: What the Research Actually Shows
• Fibromyalgia: Causes, Diagnosis, and the Complete Treatment Guide
• Hyperbaric Oxygen Therapy (HBOT): How It Works, What It Treats, and What the Evidence Shows
• Joint Pain: Causes, Diagnosis, and the Full Treatment Spectrum
• Low Dose Naltrexone (LDN): A Comprehensive Guide to Uses, Dosing, Evidence, and Side Effects
• Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment